2553 related articles for article (PubMed ID: 11782374)
1. Chemopreventive properties of a selective inducible nitric oxide synthase inhibitor in colon carcinogenesis, administered alone or in combination with celecoxib, a selective cyclooxygenase-2 inhibitor.
Rao CV; Indranie C; Simi B; Manning PT; Connor JR; Reddy BS
Cancer Res; 2002 Jan; 62(1):165-70. PubMed ID: 11782374
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of cyclooxygenase-2 inhibitor for potential chemopreventive properties in colon carcinogenesis.
Reddy BS; Rao CV; Seibert K
Cancer Res; 1996 Oct; 56(20):4566-9. PubMed ID: 8840961
[TBL] [Abstract][Full Text] [Related]
3. Chemoprevention of colon cancer by specific cyclooxygenase-2 inhibitor, celecoxib, administered during different stages of carcinogenesis.
Reddy BS; Hirose Y; Lubet R; Steele V; Kelloff G; Paulson S; Seibert K; Rao CV
Cancer Res; 2000 Jan; 60(2):293-7. PubMed ID: 10667579
[TBL] [Abstract][Full Text] [Related]
4. Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, against colon carcinogenesis.
Kawamori T; Rao CV; Seibert K; Reddy BS
Cancer Res; 1998 Feb; 58(3):409-12. PubMed ID: 9458081
[TBL] [Abstract][Full Text] [Related]
5. Chemoprevention of colonic aberrant crypt foci by an inducible nitric oxide synthase-selective inhibitor.
Rao CV; Kawamori T; Hamid R; Reddy BS
Carcinogenesis; 1999 Apr; 20(4):641-4. PubMed ID: 10223193
[TBL] [Abstract][Full Text] [Related]
6. Prevention of colon cancer by low doses of celecoxib, a cyclooxygenase inhibitor, administered in diet rich in omega-3 polyunsaturated fatty acids.
Reddy BS; Patlolla JM; Simi B; Wang SH; Rao CV
Cancer Res; 2005 Sep; 65(17):8022-7. PubMed ID: 16140976
[TBL] [Abstract][Full Text] [Related]
7. Chemoprevention of colon cancer by a glutathione conjugate of 1,4-phenylenebis(methylene)selenocyanate, a novel organoselenium compound with low toxicity.
Rao CV; Wang CQ; Simi B; Rodriguez JG; Cooma I; El-Bayoumy K; Reddy BS
Cancer Res; 2001 May; 61(9):3647-52. PubMed ID: 11325834
[TBL] [Abstract][Full Text] [Related]
8. Modulation of experimental colon tumorigenesis by types and amounts of dietary fatty acids.
Rao CV; Hirose Y; Indranie C; Reddy BS
Cancer Res; 2001 Mar; 61(5):1927-33. PubMed ID: 11280748
[TBL] [Abstract][Full Text] [Related]
9. Preventive potential of wheat bran fractions against experimental colon carcinogenesis: implications for human colon cancer prevention.
Reddy BS; Hirose Y; Cohen LA; Simi B; Cooma I; Rao CV
Cancer Res; 2000 Sep; 60(17):4792-7. PubMed ID: 10987288
[TBL] [Abstract][Full Text] [Related]
10. Effects of adlay on azoxymethane-induced colon carcinogenesis in rats.
Shih CK; Chiang W; Kuo ML
Food Chem Toxicol; 2004 Aug; 42(8):1339-47. PubMed ID: 15207385
[TBL] [Abstract][Full Text] [Related]
11. Enhancement of experimental colon cancer by genistein.
Rao CV; Wang CX; Simi B; Lubet R; Kelloff G; Steele V; Reddy BS
Cancer Res; 1997 Sep; 57(17):3717-22. PubMed ID: 9288778
[TBL] [Abstract][Full Text] [Related]
12. Molecular changes in the early stage of colon carcinogenesis in rats treated with azoxymethane.
Kishimoto Y; Morisawa T; Hosoda A; Shiota G; Kawasaki H; Hasegawa J
J Exp Clin Cancer Res; 2002 Jun; 21(2):203-11. PubMed ID: 12148579
[TBL] [Abstract][Full Text] [Related]
13. Inhibitory effect of caffeic acid esters on azoxymethane-induced biochemical changes and aberrant crypt foci formation in rat colon.
Rao CV; Desai D; Simi B; Kulkarni N; Amin S; Reddy BS
Cancer Res; 1993 Sep; 53(18):4182-8. PubMed ID: 8364913
[TBL] [Abstract][Full Text] [Related]
14. Altered expression of beta-catenin, inducible nitric oxide synthase and cyclooxygenase-2 in azoxymethane-induced rat colon carcinogenesis.
Takahashi M; Mutoh M; Kawamori T; Sugimura T; Wakabayashi K
Carcinogenesis; 2000 Jul; 21(7):1319-27. PubMed ID: 10874009
[TBL] [Abstract][Full Text] [Related]
15. Ursodeoxycholic acid and F(6)-D(3) inhibit aberrant crypt proliferation in the rat azoxymethane model of colon cancer: roles of cyclin D1 and E-cadherin.
Wali RK; Khare S; Tretiakova M; Cohen G; Nguyen L; Hart J; Wang J; Wen M; Ramaswamy A; Joseph L; Sitrin M; Brasitus T; Bissonnette M
Cancer Epidemiol Biomarkers Prev; 2002 Dec; 11(12):1653-62. PubMed ID: 12496057
[TBL] [Abstract][Full Text] [Related]
16. Prevention of azoxymethane-induced colon cancer by combination of low doses of atorvastatin, aspirin, and celecoxib in F 344 rats.
Reddy BS; Wang CX; Kong AN; Khor TO; Zheng X; Steele VE; Kopelovich L; Rao CV
Cancer Res; 2006 Apr; 66(8):4542-6. PubMed ID: 16618783
[TBL] [Abstract][Full Text] [Related]
17. Role of cyclooxygenase (COX)-1 and COX-2 inhibition in nonsteroidal anti-inflammatory drug-induced intestinal damage in rats: relation to various pathogenic events.
Tanaka A; Hase S; Miyazawa T; Ohno R; Takeuchi K
J Pharmacol Exp Ther; 2002 Dec; 303(3):1248-54. PubMed ID: 12438549
[TBL] [Abstract][Full Text] [Related]
18. Modifying effects of naturally occurring products on the development of colonic aberrant crypt foci induced by azoxymethane in F344 rats.
Kawamori T; Tanaka T; Hara A; Yamahara J; Mori H
Cancer Res; 1995 Mar; 55(6):1277-82. PubMed ID: 7882322
[TBL] [Abstract][Full Text] [Related]
19. Dose-response effects of the COX-2 inhibitor, celecoxib, on the chemoprevention of mammary carcinogenesis.
Abou-Issa HM; Alshafie GA; Seibert K; Koki AT; Masferrer JL; Harris RE
Anticancer Res; 2001; 21(5):3425-32. PubMed ID: 11848504
[TBL] [Abstract][Full Text] [Related]
20. Dietary fat and colon cancer: modulation of cyclooxygenase-2 by types and amount of dietary fat during the postinitiation stage of colon carcinogenesis.
Singh J; Hamid R; Reddy BS
Cancer Res; 1997 Aug; 57(16):3465-70. PubMed ID: 9270014
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
